X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (89317) 89317
Publication (9058) 9058
Book Review (1600) 1600
Book Chapter (620) 620
Conference Proceeding (169) 169
Dissertation (64) 64
Book / eBook (53) 53
Magazine Article (39) 39
Newspaper Article (23) 23
Streaming Video (19) 19
Paper (12) 12
Web Resource (12) 12
Government Document (11) 11
Trade Publication Article (10) 10
Data Set (6) 6
Newsletter (3) 3
Patent (3) 3
Presentation (3) 3
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (65665) 65665
index medicus (48231) 48231
oncology (42604) 42604
female (30911) 30911
male (25503) 25503
cancer (22164) 22164
middle aged (21985) 21985
chemotherapy (21054) 21054
aged (19524) 19524
adult (18784) 18784
phase-ii (17692) 17692
phase-ii trial (15720) 15720
treatment outcome (15126) 15126
animals (12635) 12635
antineoplastic combined chemotherapy protocols - therapeutic use (12304) 12304
care and treatment (11612) 11612
pharmacology & pharmacy (11524) 11524
antineoplastic agents - therapeutic use (10987) 10987
research (8919) 8919
medicine & public health (8283) 8283
therapy (8195) 8195
clinical trials (7862) 7862
analysis (7691) 7691
prognosis (7336) 7336
aged, 80 and over (7011) 7011
trial (6939) 6939
survival (6855) 6855
tumors (6732) 6732
health aspects (6665) 6665
hematology (6597) 6597
cisplatin (6384) 6384
radiotherapy (6366) 6366
clinical trials, phase ii as topic (6216) 6216
phase-i (6045) 6045
metastasis (5990) 5990
surgery (5966) 5966
drug therapy (5957) 5957
carcinoma (5696) 5696
neoplasm staging (5589) 5589
disease-free survival (5409) 5409
clinical trials as topic (5394) 5394
hematology, oncology and palliative medicine (5388) 5388
phase-iii trial (5267) 5267
retrospective studies (5071) 5071
combined modality therapy (4991) 4991
double-blind (4955) 4955
antineoplastic combined chemotherapy protocols - adverse effects (4783) 4783
immunotherapy (4769) 4769
phase-iii (4715) 4715
survival analysis (4712) 4712
article (4656) 4656
survival rate (4653) 4653
neoplasms - drug therapy (4598) 4598
lung neoplasms - drug therapy (4562) 4562
cancer therapies (4497) 4497
mice (4472) 4472
patients (4441) 4441
randomized controlled trials as topic (4373) 4373
breast cancer (4329) 4329
combination (4294) 4294
antineoplastic agents - pharmacology (4222) 4222
dose-response relationship, drug (4204) 4204
medicine, research & experimental (4172) 4172
cell line, tumor (4085) 4085
paclitaxel (4054) 4054
drug administration schedule (4023) 4023
apoptosis (4020) 4020
antineoplastic agents - administration & dosage (3987) 3987
clinical trials, phase iii as topic (3974) 3974
review (3885) 3885
antineoplastic agents - adverse effects (3875) 3875
antineoplastic agents (3787) 3787
cell lung-cancer (3765) 3765
breast neoplasms - drug therapy (3708) 3708
open-label (3702) 3702
studies (3687) 3687
expression (3680) 3680
radiation-therapy (3680) 3680
randomized-trial (3676) 3676
gemcitabine (3630) 3630
adolescent (3593) 3593
toxicity (3529) 3529
efficacy (3515) 3515
immunology (3472) 3472
risk factors (3469) 3469
carcinoma, non-small-cell lung - drug therapy (3427) 3427
medical research (3408) 3408
bevacizumab (3391) 3391
young adult (3387) 3387
antimitotic agents (3361) 3361
docetaxel (3350) 3350
medicine (3295) 3295
time factors (3272) 3272
neoplasm metastasis (3263) 3263
follow-up studies (3229) 3229
deoxycytidine - analogs & derivatives (3194) 3194
antibodies, monoclonal - therapeutic use (3163) 3163
mutation (3113) 3113
lung cancer (3089) 3089
cancer research (3083) 3083
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (15) 15
Online Resources - Online (15) 15
Engineering & Comp. Sci. - Stacks (10) 10
Collection Dvlpm't (Acquisitions) - Vendor file (8) 8
UofT at Mississauga - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
Aerospace - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Law (Bora Laskin) - Stacks (1) 1
Mathematical Sciences - Stacks (1) 1
Physics - Stacks (1) 1
Robarts - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Trillium Health Centre - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (88150) 88150
French (848) 848
German (631) 631
Japanese (446) 446
Spanish (107) 107
Polish (58) 58
Italian (51) 51
Chinese (37) 37
Russian (26) 26
Korean (19) 19
Hungarian (14) 14
Portuguese (12) 12
Czech (7) 7
Turkish (6) 6
Dutch (5) 5
Lithuanian (4) 4
Slovenian (3) 3
Finnish (2) 2
Norwegian (2) 2
Serbian (2) 2
Esperanto (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 07/2015, Volume 15, Issue 1, pp. 511 - 511
Journal Article
Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 2, pp. 234 - 242
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2005, Volume 23, Issue 28, pp. 7199 - 7206
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 99, pp. 41 - 45
Journal Article
Circulation: Heart Failure, ISSN 1941-3289, 04/2017, Volume 10, Issue 4, pp. 1 - 8
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2015, Volume 33, Issue 32, pp. 3817 - 3825
Journal Article
Cancer, ISSN 0008-543X, 10/2014, Volume 120, Issue 19, pp. 2980 - 2985
BACKGROUND Targeting a single pathway in pancreatic adenocarcinoma (PC) is unlikely to affect its natural history. We tested the hypothesis that simulataneous... 
pancreatic cancer | erlotinib signaling | randomized phase II | IGF‐1R | cixutumumab | EGFR | targeted treatment | Erlotinib signaling | Targeted treatment | Randomized phase II | Pancreatic cancer | Cixutumumab | IGF-1R | CARCINOMA-CELLS | DUCTAL ADENOCARCINOMA | MONOCLONAL-ANTIBODY | SINGLE-AGENT CETUXIMAB | BREAST-CANCER | INHIBITION | K-RAS | ONCOLOGY | THERAPEUTIC TARGET | C-MET | RESISTANCE | Erlotinib Hydrochloride | Pancreatic Neoplasms - metabolism | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptor, Epidermal Growth Factor - drug effects | Male | Insulin-Like Growth Factor I - drug effects | Pancreatic Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - metabolism | Adenocarcinoma - metabolism | Adult | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - pathology | Kaplan-Meier Estimate | Treatment Outcome | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease-Free Survival | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Insulin-Like Growth Factor I - metabolism | Index Medicus | Abridged Index Medicus
Journal Article